Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.
Dynavax Technologies (Nasdaq: DVAX), una società biofarmaceutica in fase commerciale focalizzata sullo sviluppo di vaccini, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 16:30 ET / 13:30 PT lo stesso giorno. Le parti interessate possono accedere alla trasmissione attraverso il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per 30 giorni. Si consiglia ai partecipanti di registrarsi e collegarsi 10 minuti prima della chiamata.
Dynavax Technologies (Nasdaq: DVAX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de vacunas, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, después del cierre del mercado en Estados Unidos. La compañía llevará a cabo una llamada en conferencia y una transmisión en vivo a las 4:30 p.m. ET / 1:30 p.m. PT ese mismo día. Las partes interesadas pueden acceder a la transmisión a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible durante 30 días. Se aconseja a los participantes que se registren y se conecten 10 minutos antes de la llamada.
다이나박스 테크놀로지(Nasdaq: DVAX)는 백신 개발에 중점을 둔 상업 단계 생명공학 회사로, 2024년 11월 7일 목요일 미국 시장 마감 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET/오후 1시 30분 PT에 컨퍼런스 콜 및 웹캐스트를 개최합니다. 관심 있는 당사자는 회사 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 30일 동안 재생할 수 있습니다. 참가자는 통화 10분 전에 등록하고 연결할 것을 권장합니다.
Dynavax Technologies (Nasdaq: DVAX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de vaccins, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre de 2024 le jeudi 7 novembre 2024, après la fermeture du marché américain. L'entreprise animera une conférence téléphonique et un webinaire le même jour à 16h30 ET / 13h30 PT. Les parties intéressées peuvent accéder au webinaire via le site web des relations investisseurs de l'entreprise, avec un enregistrement disponible pendant 30 jours. Il est conseillé aux participants de s'inscrire et de se connecter 10 minutes avant l'appel.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung von Impfstoffen konzentriert, hat angekündigt, dass es am Donnerstag, den 7. November 2024, nach Börsenschluss in den USA seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz und einen Webcast veranstalten. Interessierte Parteien können über die Website der Investorenbeziehungen des Unternehmens auf den Webcast zugreifen, der 30 Tage lang verfügbar ist. Den Teilnehmern wird geraten, sich 10 Minuten vor der Konferenz anzumelden und zu verbinden.
- None.
- None.
Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-7-2024-302286555.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax (DVAX) report Q3 2024 earnings?
What time is Dynavax's (DVAX) Q3 2024 earnings call?
How can I access Dynavax's (DVAX) Q3 2024 earnings webcast?
